Their primary focus, however, was on the 821 individuals who had ever used a GLP-1 drug
Demand for NHS weight loss injections creates practical workload for GP practices and PCNs
However, widespread urticaria, mucosal involvement, or systemic symptoms such as dyspnea warrant immediate evaluation
Nearly 80% of GLP-1 users conduct product or health research to support their weight loss goals
It chimes with a peer-reviewed study from Cornell University published last year, which found that US households with at least one member using weight-loss drugs spent 5% less on groceries within six months of starting the medication, with that rising to 8% among higher income families
In clinical trials, people lost up to 28.7% of their body weight after 68 weeks